UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2024 P 1128-15
Program Prior Authorization/Notification
Medication *Actemra® (tocilizumab) and Tyenne® (tocilizumab-aazg)
*This program applies to the subcutaneous formulation of tocilizumab.
P&T Approval Date 2/2014, 2/2015, 3/2016, 3/2017, 7/2017, 7/2018, 7/2019, 7/2020,
4/2021, 4/2022, 4/2023, 7/2023, 10/2024, 12/2024
Effective Date 4/1/2025
1. Background:
Tocilizumab [Actemra (tocilizumab) and Tyenne (tocilizumab-aazg)] is an interleukin-6 (IL-6)
receptor antagonist, available in both an intravenous and a subcutaneous formulation.
Subcutaneous formulations of tocilizumab are indicated for the treatment of adult patients with
moderately to severely active rheumatoid arthritis who have had an inadequate response to one
or more disease-modifying anti-rheumatic drugs (DMARDs). It is also indicated for giant cell
arteritis in adult patients, the treatment of active polyarticular juvenile idiopathic arthritis
(PJIA) and active systemic juvenile idiopathic arthritis (SJIA) in patients 2 years of age and
older, and for slowing the rate of decline in pulmonary function in adult patients with systemic
sclerosis-associated interstitial lung disease (SSc-ILD).
2. Coverage Criteriaa:
A. Giant Cell Arteritis (GCA)
1. Initial Authorization
a. Actemra or Tyenne will be approved based on both of the following criteria:
(1) Diagnosis of giant cell arteritis
-AND-
(2) Patient is not receiving Actemra or Tyenne in combination with another
targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia
(certolizumab), Simponi (golimumab), Xeljanz (tofacitinib), Olumiant
(baricitinib), Rinvoq (upadacitinib)]
Authorization will be issued for 12 months.
2. Reauthorization
a. Actemra or Tyenne will be approved based on both of the following criteria:
(1) Documentation of positive clinical response to Actemra or Tyenne therapy
-AND-
© 2024 UnitedHealthcare Services, Inc.
1
(2) Patient is not receiving Actemra or Tyenne in combination with another
targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia
(certolizumab), Simponi (golimumab), Xeljanz (tofacitinib), Olumiant
(baricitinib), Rinvoq (upadacitinib)]
Authorization will be issued for 12 months.
B. Rheumatoid Arthritis (RA)
1. Initial Authorization
a. Actemra or Tyenne will be approved based on all of the following criteria:
(1) Diagnosis of moderately to severely active rheumatoid arthritis
-AND-
(2) Patient has had an inadequate response to one or more disease-modifying anti-
rheumatic drugs (DMARDs) (e.g., methotrexate, leflunomide, sulfasalazine)^
-AND-
(3) Patient is not receiving Actemra or Tyenne in combination with another
targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab),
Simponi (golimumab), Orencia (abatacept), adalimumab, Xeljanz (tofacitinib),
Olumiant (baricitinib), Rinvoq (upadacitinib)]
Authorization will be issued for 12 months.
2. Reauthorization
a. Actemra or Tyenne will be approved based on both of the following criteria:
(1) Documentation of positive clinical response to Actemra or Tyenne therapy
-AND-
(2) Patient is not receiving Actemra or Tyenne in combination with another
targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab),
Simponi (golimumab), Orencia (abatacept), adalimumab, Xeljanz (tofacitinib),
Olumiant (baricitinib), Rinvoq (upadacitinib)]
Authorization will be issued for 12 months.
C. Polyarticular Juvenile Idiopathic Arthritis (PJIA)
1. Initial Authorization
a. Actemra or Tyenne will be approved based on both of the following criteria:
© 2024 UnitedHealthcare Services, Inc.
2
(1) Diagnosis of active polyarticular juvenile idiopathic arthritis
-AND-
(2) Patient is not receiving Actemra or Tyenne in combination with another
targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia
(certolizumab), Simponi (golimumab), Orencia (abatacept), adalimumab,
Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib)]
Authorization will be issued for 12 months.
2. Reauthorization
a. Actemra or Tyenne will be approved based on both of the following criteria:
(1) Documentation of positive clinical response to Actemra or Tyenne therapy
-AND-
(2) Patient is not receiving Actemra or Tyenne in combination with another
targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia
(certolizumab), Simponi (golimumab), Orencia (abatacept), adalimumab,
Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib)]
Authorization will be issued for 12 months.
D. Systemic Juvenile Idiopathic Arthritis (SJIA)
1. Initial Authorization
a. Actemra or Tyenne will be approved based on both of the following criteria:
(1) Diagnosis of active systemic juvenile idiopathic arthritis
-AND-
(2) Patient is not receiving Actemra or Tyenne in combination with another
targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia
(certolizumab), Simponi (golimumab), Orencia (abatacept), adalimumab,
Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib)]
Authorization will be issued for 12 months.
2. Reauthorization
a. Actemra or Tyenne will be approved based on both of the following criteria:
(1) Documentation of positive clinical response to Actemra or Tyenne therapy
-AND-
© 2024 UnitedHealthcare Services, Inc.
3
(2) Patient is not receiving Actemra or Tyenne in combination with another
targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia
(certolizumab), Simponi (golimumab), Orencia (abatacept), adalimumab,
Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib)]
Authorization will be issued for 12 months.
E. Systemic sclerosis-associated interstitial lung disease (SSc-ILD)
1. Initial Authorization
a. Actemra or Tyenne will be approved based on the following criterion:
(1) Diagnosis of systemic sclerosis-associated interstitial lung disease (SSc-ILD)
-AND-
(2) Patient is not receiving Actemra or Tyenne in combination with another
targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia
(certolizumab), Simponi (golimumab), Orencia (abatacept), adalimumab,
Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib)]
Authorization will be issued for 12 months.
2. Reauthorization
a. Actemra or Tyenne will be approved based on both of the following criteria:
(1) Documentation of positive clinical response to Actemra or Tyenne therapy.
-AND-
(2) Patient is not receiving Actemra or Tyenne in combination with another
targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia
(certolizumab), Simponi (golimumab), Orencia (abatacept), adalimumab,
Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib)]
Authorization will be issued for 12 months.
a State mandates may apply. Any federal regulatory requirements and the member specific
benefit plan coverage may also impact coverage criteria. Other policies and utilization
management programs may apply.
^ Tried/Failed alternative(s) are supported by FDA labeling.
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-
authorization based solely on previous claim/medication history, diagnosis codes (ICD-10)
© 2024 UnitedHealthcare Services, Inc.
4
and/or claim logic. Use of automated approval and re-approval processes varies by
program and/or therapeutic class.
• Supply limits and/or Step Therapy may be in place.
• The intravenous infusion is typically covered under the medical benefit. Please refer to
the United Healthcare Drug Policy for Tocilizumab.
4. References:
1. Actemra [package insert]. South San Francisco, CA: Genentech, Inc.; September 2024.
2. Tyenne [package insert]. Lake Zurich, IL: Fresenius Kabi USA, LLC; March 2024
Program Prior Authorization/Notification - Actemra (tocilizumab) and Tyenne
(tocilizumab-aazg)
Change Control
2/2014 New program.
9/2014 Administrative change - Tried/Failed exemption for State of New Jersey
removed.
2/2015 Annual review with no change to coverage criteria. Minor reformatting.
Updated references.
3/2016 Annual review with no change to the coverage criteria. Updated
background. Updated statement regarding scope of the program.
Added reference to UHC drug policy for intravenous infusions.
Updated references.
3/2017 Annual review with no change to the coverage criteria. Updated
background and references.
7/2017 Added coverage criteria for giant cell arteritis. Updated background
and references.
7/2018 Annual review. Added coverage for PJIA. Updated references.
7/2019 Annual review. Added coverage criteria for SJIA. Updated background
and references.
7/2020 Annual review. Updated authorization issue to 12 months for renewal.
Updated reference.
4/2021 Added coverage criteria for systemic sclerosis-associated interstitial
lung disease. Updated background and references.
4/2022 Annual review. Updated background to reflect both formulations being
approved for GCA. Updated references.
4/2023 Annual review with no change to coverage criteria. Updated listed
examples from Humira to adalimumab and added Rinvoq as JAK-I
example. Updated reference. Added state mandate footnote.
7/2023 Updated not receiving in combination language to targeted
immunomodulator and updated examples.
10/2024 Annual review with no change to coverage criteria. Updated reference.
12/2024 Added Tyenne to coverage criteria with Actemra. Added T/F footnote.
Updated background and references.
© 2024 UnitedHealthcare Services, Inc.
5